The FDA approved atezolizumab with chemotherapy as adjuvant treatment for stage III dMMR colon cancer following the phase III ATOMIC trial. The decision follows results indicating a 50% reduction in risk of recurrence or death, establishing an immunotherapy-led option in a genetically defined colorectal subtype. For biotech and pharma teams developing in dMMR disease, the approval signals continued regulatory willingness to incorporate mismatch repair biology into curative-intent strategies. It also raises the bar for next-line comparisons in post-surgical management where durability endpoints and biomarker stratification will likely remain central.